ACE Inhibitor or Angiotensin receptor antagonist

DRUG2 trials

Sponsors

Peking University First Hospital, The Affiliated Hospital of Xuzhou Medical University

Conditions

IgA NephropathyIgA Nephropathy (IgAN)Immunosuppressive TreatmentProteinuria in Nephrotic Range

Phase 3

To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy

Active, not recruitingNCT07098897

The Affiliated Hospital of Xuzhou Medical UniversityIgA Nephropathy (IgAN)

Start: 2024-08-01End: 2025-09-30Updated: 2025-08-01

Unknown Phase

Registry of IgA Nephropathy in Chinese Children

Peking University First HospitalIgA Nephropathy, Immunosuppressive Treatment, Proteinuria in Nephrotic Range

Start: 2016-01-31End: 2024-12-31Target: 1200Updated: 2023-12-06